- Julius Group, Noble Biomaterials to launch high-quality antiviral PPE
- Ardigen, CVC collaborate to develop SARS-CoV-2 vaccine
- PHC Group strengthens life sciences biz in Asia
- Carromex unveils leads for rapid drug analysis and discovery
- Merck opens largest M Lab collaboration center in Shanghai
- Hong Kong approves Eisai's anti-insomnia drug Dayvigo
- Chemopharm ramps up efforts to fight COVID-19
- Aichi Cancer Center, NEC study advanced cancer immunotherapy
- Carmine Therapeutics teams up with Takeda for non-viral gene therapies
- NIH launches clinical trials network to test COVID-19 vaccines
- WellsCare targets smart health device market
- Polaris Biology pushes next-gen T cell detection reagents
- GBC develops novel molecular testing kit for COVID-19
- Caution on viewing COVID-19 vaccine as silver bullet: NUS webinar
-
World | 20 March 2020 | Influencers
Eppendorf is investing disproportionately in expansion of its global locations, particularly in Asia
Congratulations on your new role. What are the main agendas behind the recently announced dual leadership at E...Read more
-
Australia | 10 July 2020 | News
Carromex unveils leads for rapid drug analysis and discovery
Carromex, a mathematical research-based innovation company based in Australia, unveiled a new cloud-based...Read more
-
New Zealand | 10 July 2020 | News
Ardigen, CVC collaborate to develop SARS-CoV-2 vaccine
Poland headquartered Ardigen and New Zealand based CVC (COVID-19 Vaccine Corporation) have anno...Read more
-
World | 05 March 2020 | News
FDA bans ESDs for self injurious behaviour
After careful consideration, the U.S. Food and Drug Administration (FDA) has published a final rule to ban ele...Read more
-
Europe | 06 March 2020 | News
Viroclinics Biosciences and DDL Diagnostic Lab join forces
Netherlands based Viroclinics Biosciences, a leading virology contract research organization, has announced th...Read more
Firms racing to develop antibody treatment for COVID-19
The Coronavirus COVID-19 has raged the world and has infected 8,993,659 cases and killed 469,587 (as of June 23, 2020. Source World Health Organization (WHO)). Pharma firms, scientists and governments all over the world are racing to find a cure for the virus. The entire world is waiting for the vaccine; Moderna’s mRNA vaccine will begin phase III study in July. Amidst all this, some biopharma companies are pushing to develop antibody based treatments for the virus. Does that have any merit? Why are firms putting billions of dollars into it when vaccines are the ultimate solution? Let’s find out.
